Drug test for IgA? No—anti-PLA2R positive immune kidney disease
Part of Immune system & allergy, Kidney & urinary clinical trials.
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 85 years old.
- You were diagnosed with iMN within the last 6 months.
- Your blood test must show anti-PLA2 receptor positive results within the last 6 months.
- You must have severe protein in your urine plus specific kidney lab results, and kidney filtering (eGFR) must be above 30.
- You must live in Denmark or Norway or Sweden (this trial has country-specific rules for women).
- Your blood pressure must be controlled, and you must have been on an ACE-inhibitor or ARB for at least 1 month (or you could not take it due to side effects).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental pill (NTQ5082) for people with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
Hear when a new Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.